Department of Biochemistry & Molecular Biology, University of Oklahoma Health Science Center, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA.
Cancer Invest. 2012 Feb;30(2):180-8. doi: 10.3109/07357907.2011.633294. Epub 2011 Dec 7.
Goals of this study were to analyze the ability of mass spectrometry serum profiling to distinguish non-small cell lung adenocarcinoma from squamous cell carcinoma patients and healthy controls. Sera were obtained from 19 adenocarcinoma patients, 24 squamous cell carcinoma patients, and 21 controls. Identifications of significant mass-to-charge ratio (m/z) peak differences between these groups were performed using t-tests. A "leave one out" cross-validation procedure yielded discriminatory lung adenocarcinoma versus squamous cell carcinoma p and ROC curve values of <.0001 and 0.92, respectively. Test sensitivity and specificity were 84% and 79%, respectively. This approach could aid in lung cancer diagnosis and sub-typing.
本研究的目的是分析质谱血清分析区分非小细胞肺癌腺癌与鳞癌患者和健康对照的能力。从 19 名腺癌患者、24 名鳞癌患者和 21 名对照中获得血清。使用 t 检验对这些组之间的显著质荷比 (m/z) 峰差异进行鉴定。“留一法”交叉验证程序得出的鉴别肺腺癌与鳞癌的 p 值和 ROC 曲线值分别为 <.0001 和 0.92。测试的敏感性和特异性分别为 84%和 79%。这种方法可以辅助肺癌的诊断和亚型分类。